- Conditions
- Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
- Interventions
- ONO-9054, Placebo
- Drug
- Lead sponsor
- Ono Pharma USA Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 3
- States / cities
- Costa Mesa, California • Newport Beach, California • Santa Ana, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 2,823
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Rilematovir, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Bakersfield, California + 28 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- Sabyasachi Sen
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Joint Discomfort, Quality of Life (QOL)
- Interventions
- Supplement 2, Supplement 3, Supplement 1
- Dietary Supplement
- Lead sponsor
- Ultra Botanica LLC
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- Biological
- Lead sponsor
- Keros Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more
- Conditions
- Healthy Participants
- Interventions
- AZD5004, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Hepatitis B
- Interventions
- TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Bradenton, Florida • Flushing, New York • Philadelphia, Pennsylvania
- Conditions
- Diabetic Macular Edema
- Interventions
- Octreotide (drug), Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Healthy Adult Subjects
- Interventions
- ONO-9054
- Drug
- Lead sponsor
- Ono Pharma USA Inc
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Influenza, COVID-19
- Interventions
- Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 8,795 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 106
- States / cities
- Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
- Conditions
- Hyperuricemia, Gout
- Interventions
- ALLN-346, Placebo
- Drug
- Lead sponsor
- Allena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Smokeless Tobacco Use
- Interventions
- Nicotine Lozenges, Placebo lozenge
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Eugene, Oregon
- Conditions
- Pyoderma Gangrenosum
- Interventions
- gevokizumab, Placebo, gevokizumab open-label
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Oceanside, California • Tampa, Florida • Macon, Georgia + 4 more
- Conditions
- COVID-19
- Interventions
- Nitazoxanide, Placebo, Vitamin Super B-Complex
- Drug · Dietary Supplement
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Fort Lauderdale, Florida • The Bronx, New York
- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Interventions
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion
- Biological · Drug · Other
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 4 more
- Conditions
- Hypertension (HTN)
- Interventions
- Firibastat (QGC001) Period 1
- Drug
- Lead sponsor
- Quantum Genomics SA
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Manassas, Virginia
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Prolonged QTc Interval, Pharmacokinetic
- Interventions
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Alzheimer Disease
- Interventions
- BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo
- Drug
- Lead sponsor
- Tetra Discovery Partners
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- COPD
- Interventions
- Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
- Combination Product
- Lead sponsor
- Phargentis SA
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
- Conditions
- Obesity
- Interventions
- BMS-830216, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Epilepsy
- Interventions
- BIA 2-093, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Bial - Portela C S.A.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- HIV, Herpes Simplex Infections
- Interventions
- MB66, Placebo Film
- Drug
- Lead sponsor
- KBio Inc
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 652
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more